3rd Targeted Protein Degradation Europe Summit

The Targeted Protein Degradation Europe Summit returns to London for its 3rd year, providing a central touchpoint to obtain critical updates and learnings from key European biopharma leaders, and delve into vital early discovery and preclinical challenges on the road to robust clinical pipelines.

As a more technical and mechanistic centred forum, this summit is built with European TPD professionals and global technical TPD experts in mind, as these two tracks, three-day forum will navigate through:

Enhance the Selectivity, Bioavailability and PKPD to Ensure Safety, Efficacy and Potency

Progress Computational Modelling of TPD to Improve Structural Predictions and Understand Selectivity

Optimising Degrader Design via Enhanced Assay Selection and Development

Emerging Degradation Strategies from AUTACs and LYTAC's

Emerging Targets and Indications for Protein Degradation Beyond Oncology

As the first ever fully in-person meeting, 160+ leading Medicinal Chemists, Biologists, Heads of Discovery and R&D and Pre-Clinical and Translational Development experts from Europe and across the globe will unite. Make sure you are a part of this community to strengthen your pipelines and stay ahead of the curve as the next generation of protein degraders are defined.

URLs:
Brochure: https://go.evvnt.com/1409118-0?pid=10018
Website: https://go.evvnt.com/1409118-1?pid=10018
Tickets: https://go.evvnt.com/1409118-2?pid=10018

Prices:
Drug Developer Pricing - Conference Only: GBP 2599.00,
Drug Developer Pricing - Conference + Focus Day: GBP 3796.00,
Academic Pricing - Conference Only: GBP 2099.00,
Academic Pricing - Conference + Focus Day: GBP 2996.00,
Standard Pricing - Conference Only: GBP 2999.00,
Standard Pricing - Conference + Focus Day: GBP 4496.00

Speakers: Gwenn Hansen, Chief Scientific Officer, Nurix Therapeutics, Grasilda Zenkeviciutė, Senior Scientist, Proxygen, Ian Churcher, Chief Scientific Officer, Amphista Therapeutics, Paul Novick, Director, Cheminformatics and Machine Learning, Nurix Therapeutics, Gali Prag, Chief Scientific Officer, COLTAC Therapeutics LTD / Tel Aviv University, Andreas Reichel, Vice President, Head of DMPK M&S Bayer, Beth Williamson, Head of ADME, UCB Pharma, Jamie Ware, Associate Principal Scientist, AstraZeneca, Martin Schneider, Associate Director, Novartis, .Paola Martinelli, Principal Scientist, Boehringer Ingelheim, Alzbeta Tuerkova, Head of Computer- Aided Drug Design, Celeris Therapeutics, Beth Hoffman, Founder and Chief Executive Officer, Origami Therapeutics, Rob Sellar, Senior Fellow Clinical Research, University College London, Hakryul Jo, Director, Platform Biology, Kymera Therapeutics, Nicholas Edmunds, Chief Technology Officer, Mission Therapeutics, Giovanni Spagnolli, Chief Technology Officer, Sibylla Biotech, Esther Fernandez- Velando, Head of Flexible Biology Platforms, GSK, Felix Hausch, Professor Structure Based Drug Design Technical, University Darmstadt, Kevin Moreau, Director Safety Innovation and PROTAC Science Lead, AstraZeneca, William Farnaby, Principal Investigator, Centre for Targeted Protein Degradation, University of Dundee, Robin Haid, Post-Doctoral Scientist, Bayer, Benedict Cross, Chief Technology Officer, PhoreMost, Rie Schultz, Hansen Chief Scientific Officer, Aelin Therapeutics, Avishai Levy, Chief Executive Officer, Tripod Therapeutics, Priscilla Yang, Professor, Department of Microbiology and Immunology, Stanford University School of Medicine, Tauseef Butt, President and Chief Executive Officer, Progenra, Tim Miles, Head of Unmet Needs and AMR, GSK, Maria Gorna, Group Leader, University of Warsaw, Thomas Dick, Center for Discovery and Innovation Hackensack, Meridian School of Medicine and Georgetown University, Lukas Junk, Synthetic Medicinal Chemist and Post- Doctoral Student Helmholtz-Institute for Pharmaceutical Research, Saarland, Bernard Haendler, Senior Science Fellow; Research and Early Development Oncology, Bayer AG